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POINT OF VIEW: DIRECTIONS FOR RESEARCH
Cellular Transplants in China:
Observational Study from the Largest
Human Experiment in Chronic Spinal Cord
Injury
Bruce H. Dobkin, MD, Armin Curt, MD, and James Guest, MD, PhD
Background. In China, fetal brain tissue has been
transplanted into the lesions of more than 400
patients with spinal cord injury (SCI). Anecdotal
reports have been the only basis for assuming that
the procedure is safe and effective. Objective. To
compare available reports to the experiences and
objective findings of patients who received pre-
operative and postoperative assessments before
and up to 1 year after receiving cellular implants.
Methods. Independent observational study of 7
chronic SCI subjects undergoing surgery by Dr
Hongyun Huang in Beijing. Assessments included
lesion location by magnetic resonance imaging,
protocol of the American Spinal Injury Association
(ASIA), change in disability, and detailed history of
the perioperative course. Results. Inclusion and
exclusion criteria were not clearly defined, as sub-
jects with myelopathies graded ASIA A through D
and of diverse causes were eligible. Cell injection
sites did not always correlate with the level of
injury and included the frontal lobes of a subject
with a high cervical lesion. Complications, includ-
ing meningitis, occurred in 5 subjects. Transient
postoperative hypotonicity may have accounted
for some physical changes. No clinically useful
sensorimotor, disability, or autonomic improve-
ments were found. Conclusions. The phenotype
and the fate of the transplanted cells, described as
olfactory ensheathing cells, are unknown.
Perioperative morbidity and lack of functional
benefit were identified as the most serious clinical
shortcomings. The procedures observed did not
attempt to meet international standards for either a
safety or efficacy trial. In the absence of a valid
clinical trials protocol, physicians should not rec-
ommend this procedure to patients.
Key Words: Spinal cord injury—Neural transplantation—
Regeneration—Rehabilitation—Neuroplasticity—
Clinical trials—Fetal olfactory cells.
Neural cellular transplantation strategieshave been studied in patients with cau-tiously planned safety and randomized
controlled trials for Parkinson disease,1 Alzheimer
disease,2 and stroke.3 Modest axonal regeneration,
remyelination, and nonspecific behavioral effects
of implants of a variety of cell types in rat and
mouse models of spinal cord injury (SCI), as well
as other biologic strategies for neural repair, have
increased the expectations of patients and their
families that a cure for paralysis is imminent.4,5
Comparable to other new medical treatments, the
promotion of these cell-based interventions
should be dependent on rigorously performed
Copyright © 2006 The American Society of Neurorehabilitation 5
From the Department of Neurology, Neurorehabilitation and
Research Program, Geffen School of Medicine, University of
California Los Angeles, Los Angeles, CA (BHD); the Spinal Cord
Injury Center, Balgrist University Hospital, Zurich, Switzerland,
and ICORD and Division of Neurology, the University of British
Columbia, Vancouver, British Columbia, Canada (AC); and the
Neurological Surgery and the Miami Project to Cure Paralysis,
Miller School of Medicine, Miami, FL (JG).
Address correspondence to Bruce H. Dobkin, MD, Department
of Neurology, University of California Los Angeles, RNRC, 710
Westwood Plaza, Los Angeles, CA 90095-1769. E-mail:
bdobkin@mednet.ucla.edu.
Dobkin BH, Curt A, Guest J. Cellular transplants in China: obser-
vational study from the largest human experiment in chronic
spinal cord injury. Neurorehabil Neural Repair 2006;20:5-13.
DOI: 10.1177/1545968305284675
safety trials followed by well-designed random-
ized controlled trials that establish efficacy for a
defined population of patients.
Dr Hongyun Huang, a neurosurgeon in Beijing,
China, has performed cellular transplants in more
than 400 patients with SCI and 100 patients with
amyotrophic lateral sclerosis (ALS) at Chaoyang
and West Hills (Xishan) hospitals. A recent inter-
view with a writer from Nature estimated that 3000
Chinese and 1000 foreigners are awaiting his injec-
tion of what he describes as olfactory ensheathing
cells (OECs) from aborted fetuses.6 He has verbally
stated that no medical complications have
occurred and that his patients often improve, usu-
ally within 3 days of surgery. Western physicians,
scientists, and reporters who have visited Dr
Huang since 2003 have not been able to examine a
patient’s course beyond the 1st few days after sur-
gery; thus, occasional descriptions of modest post-
operative improvements are unconfirmed.
THE PROBLEM
Very little scientific and clinical information has
been made available to researchers and patients
about the experimental procedures employed by
Dr Huang, yet the number of patients who have
participated in his experiment is far larger than any
other cell transplantation strategy for any neuro-
logic disease to date. This report presents clinical
data on 7 subjects who had cellular implantations
for SCI by Huang and colleagues in 2004 and rep-
resents the largest series of cases monitored pro-
spectively by Western physicians. The findings are
compared and contrasted to the limited informa-
tion available in a published article from Dr Huang
and colleagues,7 to comments made by him at a
conference, and to media representations of his
work. This report about presurgical and
postsurgical observations, however, is not a substi-
tute for a randomized controlled trial with defined
entry criteria and blinded, predefined outcomes
using reliable and relevant measurement tools.8
The aim is to encourage a realistic evaluation of
anecdotes and of experiments performed without
controls or placebos in Beijing, as well as provide
information to physicians, researchers, patients,
disease-oriented advocacy groups, and the media
about how to weigh possible human risks and ben-
efits of invasive cell implants for neurologic dis-
eases. The case series also points to directions that
the Beijing group could take to design a
scientifically valuable study.
Case Reports
Seven patients who had already decided to have
surgery by Dr Huang were examined before and 1
or more times within 1 year after their surgical
implantations in Beijing. Conventional American
Spinal Injury Association (ASIA) tools were used to
measure strength, sensation, level of injury, and
completeness of SCI. In addition, the subjects were
assessed for changes in overall functional inde-
pendence for self-care, for sensorimotor gains
below the injury, and for autonomic and subjective
improvements noted by the subjects or their fami-
lies. Events about the postoperative hospitaliza-
tion were obtained from subjects and family mem-
bers who attended them in Beijing. A summary of
the 7 patients appears in Table 1.
Subject 1. Before surgery, subject 1 (S1) had high
tetraplegia with voluntary movement only in right
elbow flexion and bilateral trapezius elevation.
The subject was told that cells were injected into
the spinal cord at the upper (C-3) and bottom edge
(C-5) of myelomalacia, documented by magnetic
resonance imaging (MRI). In the 1st postoperative
week after cell implantation, the family reported
reduced spasms of the arms and legs. However,
the 1st 10 days after surgery were complicated by
meningitis and confusion. A cerebrospinal fluid
pleocytosis persisted during the course of 5 lumbar
punctures in the subsequent month. Three months
after surgery, right elbow flexor strength was 2 of
5, unchanged from our preoperative assessment.
However, S1 believed that this movement had
improved. The family also reported that a twitch of
wrist extension had developed on the right. At
both preoperative and postoperative examina-
tions, however, S1 had slight involuntary motion of
several fingers of each hand caused by fascicu-
lation of the intrinsic hand muscles. The family had
interpreted these movements as a sign of improve-
ment. The subject increased the range of elbow
flexion, but the increase was less than 5°. The max-
imal speed of biceps contraction for elbow flexion,
performed during a limited range of motion of 30°
without gravity, had increased from 10 flexions per
30 s to 12 flexions per 30 s, but this movement still
rapidly fatigued with any greater number of repeti-
tions. S1 had been practicing this movement daily
after surgery as part of a new physical therapy pro-
gram. A functional MRI scan performed 3 months
after surgery showed wider recruitment of activity
in bilateral primary sensorimotor cortex compared
to preoperatively for this 30° elbow movement,
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compatible with a practice effect. Chronic, burning
upper back pain gradually diminished after sur-
gery. S1 was able to reduce the daily dose of
fentanyl from 100 ug to 50 ug at 3 months and dis-
continue fentanyl by 6 months. At 10 months,
examination revealed no change in elbow
movement and no sensorimotor or functional
gains. Occasional bouts of dysautonomia were
unchanged.
Subject 2. Subject 2 (S2), who had high tetraplegia
and no motor function below C-3, received cells at
the level of the cystic myelomalacia, as well as
through 2 burr holes placed over the frontal lobes.
S2 required assistive ventilation at inspiratory pres-
sures of 12 mm Hg or greater before surgery.
Spasms of the arms and legs diminished for the 1st
7 to 10 days after surgery but reappeared. The
postoperative hospitalization was complicated by
meningitis, delirium, pneumonia, and gastrointes-
tinal bleeding, which required multiple medica-
tions for management. On returning from China,
the family believed S2 was improving and
decreased the ventilator inspiratory pressure to 8
mm Hg. Two days later, S2 was hospitalized for
pneumonia and atelectasis. After S2 recovered, in-
spiratory pressures were again maintained at
approximately 12 to 14 mm Hg. S2 believed that
the strength of the neck and trapezius muscles
above the level of the injury had improved in the
months after surgery, during which he participated
in a new daily program of physical therapy. The
mother thought that S2 had improved to be able to
extend an elbow, but the examination showed that
elbow extension only occurred passively by grav-
ity when the distal arm was held below the
horizontal. Occasional bouts of dysautonomia
were unchanged.
Subject 3. Subject 3 (S3) had an incomplete C-4
central cord injury; MRI revealed an area of
myelomalacia from C-4 to C-5 involving approxi-
mately 75% of the diameter of the cord. With exten-
sive practice during the 1st 2 years after SCI, S3 had
taken assisted steps for up to 15 m within 20 min
but had stopped training for almost 2 years prior to
cellular implantation. For about 5 days after sur-
gery in Beijing, S3 found that the chronic
hypertonicity and spasms induced by attempted
movements had diminished. The subject more eas-
ily rotated the left hand toward the mouth and
slightly everted a foot. S3 had developed head-
ache, fever, and confusion within the 1st postoper-
ative day, which suggested meningitis, and then
developed a drug rash to Cefobid. The drug was
stopped and then in error restarted, leading to a
severe maculopapular rash. Four months after
returning from Beijing, S3 initially believed that
daily stepping training was improving the ability to
take steps, but S3 still required maximal assistance.
Marked spastic paraparesis and trunk weakness
persisted and neither selective movements or step-
ping differed from the preoperative assessment. S3
discontinued all standing and walking attempts
about 6 months later and stated by telephone that
function had not improved or worsened with the
surgery.
Subject 4. Subject 4 (S4) had sustained an incom-
plete tetraplegic injury and recovered to inde-
pendent ambulation using canes. S4 was continent
but had bladder hyperactivity. S4 sought the
implantation procedure in the hope that a reduc-
tion in severe lower extremity spasticity would
ensue and improve functional ambulation. The
MRI showed myelomalacia at C-6/7. One day after
surgery, S4 thought that finger movements of the
right hand had improved. S4 experienced a febrile
reaction and headache for 2 days after surgery. In
the United States, S4 exercised regularly with a
physical therapist to try to improve walking. When
a postsurgical gait analysis was compared to the
presurgical video assessment, no clear change in
kinematics and spatiotemporal features was
found. A small improvement in light touch was
noted. Severe leg spasticity persisted.
Subject 5. Subject 5 (S5) had sustained a complete
T-7/8 thoracic injury 26 years before cellular
implantation. MRI showed a large syrinx extending
to C-3 that was clinically silent. S5 had previously
participated in an experimental program of func-
tional electrical stimulation for walking. S5 under-
went implantation at the C-3/4 level and had head-
ache and fever postoperatively. After surgery, the
sensory level was unchanged and no functional
changes had developed.
Subject 6. Subject 6 (S6) had a complete lesion at T-
11. S6 developed headache and fever immediately
after surgery and was placed on antibiotics. S6
reported that the big toes of both feet occasionally
moved after surgery. Repeated clinical muscle test-
ing and needle electromyography (EMG) record-
ings disclosed no difference between the
preoperative and postoperative assessments, and
an examination found no new voluntary muscle
8 Neurorehabilitation and Neural Repair 20(1); 2006
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activation, sensory change, or functional improve-
ment after surgery, even with 6 months of postop-
erative rehabilitation. Hypertonicity was not a clin-
ical problem for this subject before or after
surgery.
Subject 7. Subject 7 (S7) had an incomplete ASIA B
lesion at C6. No spasms were present before or
after surgery. S7 reported that knee extensor mus-
cle function could be elicited after surgery when
stretching the abdominal muscles by lying back-
ward. Both clinical muscle testing and EMG
recordings, including tests taken in this position,
revealed no changes. Motor-evoked potentials
continued to be absent, and sensory-evoked
potentials continued to be delayed.
Methodological Considerations
Drawn from Case Reports
From the perspective of evidence-based medi-
cine, this observational study cannot, of course,
represent either the complete experience of Dr
Huang’s surgical group or the outcomes deter-
mined by a proper randomized controlled trial.
The observations, however, point to problematic
methodology and scientific issues in the Beijing
reports that could be addressed in future trials of
cellular transplantation for SCI.
No clear clinical or anatomical selection
requirements for this surgical procedure, either
inclusion or exclusion criteria, were apparent for
this series of participants. Subjects who had incom-
plete SCI and retained functional movements
below the lesion were eligible, along with those
with a complete traumatic SCI. Although the pres-
ence of a focal region of myelomalacia permitting
injection of implants into the caudal and rostral
ends of the cavity had been indicated by Dr Huang
in his publication and lectures as anatomical entry
criterion, this criterion clearly was not the only cri-
teria utilized. For example, S5 had cells placed at
the rostral C-3 level of an asymptomatic
syringomyelia, but the SCI had caused paraplegia
at T-7. S2 had cells placed bilaterally into the
frontal lobes of the brain.
Medical complications affected at least 5 of the 7
subjects evaluated. These adverse events included
meningitis with headache that required antibiotics
and repeated cerebrospinal fluid examinations,
drug-induced rash, gastrointestinal hemorrhage,
and pneumonia. Other common complications of
spinal surgery from general anesthesia, dural
leaks, and wound infections could not be ascer-
tained from the information given to patients and
families. Dr Guest observed in Beijing a case of
wound breakdown, a case of meningitis after sur-
gery, and a reduction in leg function in 1 of 12 sub-
jects whom he and colleagues formally examined.
No comprehensive plan for preoperative and
long-term postoperative assessments of impair-
ments and disabilities by the Huang group was
appreciated for the 7 subjects. Follow-up did not
extend beyond the 1st 2 to 4 weeks after surgery.
More objective assessments of impairments and
disabilities before surgery, as well as routinely dur-
ing the 1st year after surgery, are necessary to
determine the short- or long-term risks and bene-
fits of cellular implants followed by rehabilitation
efforts.
Functional effectiveness of the implants was not
evident in the 7 subjects, as only 1 objective
change in impairment occurred. S4, who was
graded ASIA D before surgery and walked over
ground, developed a very slight change from
twitch of the tibialis anterior muscle to partial
ankle motion, but not against gravity, and a small
dermatomal change in light touch. Symptomati-
cally, S1 had less need for pain medications in the
months after surgery to manage a focal area of pos-
terior trunk dysesthesia several segments below
the level of the lesion. Physiologic fluctuations that
are common in patients with chronic SCI or some
aspect of the procedure may account for these
changes.
Publication from Dr Huang
Huang and colleagues reported in the Chinese
Medical Journal on their transplantation of OECs
into 171 subjects (114 with cervical lesions) with
SCI. Ages ranged from 2 years to 64 years, with a
mean of 35 years.7 These subjects had traumatic
injuries or epidural hematomas from 6 months to
18 years duration, with a residual focal cystic
region of myelomalacia. No information about pre-
operative ASIA measures and stability of neuro-
logic impairments and functional disabilities was
provided. The article states that before implemen-
tation, subjects had received neurotrophic factor,
nerve growth factor, or spinal cord decompres-
sion. No details were provided about the origin of
the growth factors, timing of administration, dose,
effects, or complications. The report states that
500 000 cultured fetal cells from the “glomerular
layer of the olfactory bulb” were implanted after
Neurorehabilitation and Neural Repair 20(1); 2006 9
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laminectomy into the rostral and caudal ends of
the cyst. Higher scores on the ASIA scales of motor,
light touch, and pinprick impairment, regardless of
age, were found by 2 to 8 weeks after surgery. The
motor scores of the patients from age 20 to 50 years
changed by a mean of 8 ± 8 points, and only these
mean changes were listed. Interrater reliability for
this measurement was not described, and the
assessors were aware that surgery had taken place.
Disability-related outcomes or information about
autonomic and bladder function were not
reported. It has to be concluded that widely
accepted clinical trial protocols were not utilized
to define subject eligibility and to objectively
assess any complications and changes in
disability.9,10
Oral Reports from Dr Huang
In February 2004, Dr Huang lectured to a meet-
ing of a consortium of national research and advo-
cacy groups called the International Campaign for
Cures of Spinal Cord Injury Paralysis (ICCP) in Van-
couver.10 He reported that each subject received
olfactory bulb cells obtained from 2 aborted
fetuses at 14 to 16 weeks gestation. No blood type
or tissue matching between the fetuses and the
patients was performed. After the cells were grown
in tissue culture, they were injected into the rostral
and caudal ends of the region of myelomalacia as
defined by MRI. Dr Huang reported no adverse
reactions in more than 500 implantations. He
showed brief video clips of 5 patients whom he
believed had made very modest improvements
within several days after surgery. Dr Huang was
not able to explain a mechanism by which the
transplants would have had such a rapid benefit.
Two subjects improved by day 2 after injection.
Before surgery, they were tested supine and
attempted to flex the elbow by dragging the arm
over their chest. After surgery, they were seated
with the arm supported by an examiner and
appeared able to partially flex against gravity.
Another subject had marked hypertonicity and
clonus and stood with 2 helpers. Two days after
surgery, stiffness appeared reduced and the sub-
ject took several assisted steps with 2 helpers.
Because of the manner in which preoperative and
postoperative assessments differed, any interpre-
tation of the degree or sort of improvement was
difficult to interpret.
Other Observational and
Media Reports
Regarding medical complications, Dr Huang
said, “No problems with the cells; maybe we have
complications of the surgery—infection of the
area, leakage of the cerebrospinal fluid. The gen-
eral complications of other surgery.”11 Dr Guest
observed Dr Huang while Dr Huang performed a
standard surgical exposure of the spinal cord and
injected cells using a tuberculin syringe, a pediatric
needle, and IV tubing in 4 patients and commented
that the surgical technique and anesthetic adminis-
tration were of high quality. As noted, however, he
observed a variety of perioperative complications.
In add i t ion , he found tha t h igh dose
methylprednisolone was administered to some
subjects at the time of surgery. The use of this drug
is controversial and has been linked to medical
complications.12 Dr Wise Young told the Detroit
Free Press that he believed that as many as 3 SCI
and 10 ALS recipients may have died from the pro-
cedure.13 This information needs verification to
gauge the real risk of mortality. Open reporting of
medical complications is feasible for physicians in
the People’s Republic of China, where morbidity
and mortality have been published by other Chi-
nese physicians for medical and surgical
interventions.14,15
The nature of the implanted cells is unclear in
the publication and verbal reports of Huang and
colleagues. In a Technology Review article,11 Dr
Huang said, “We get the olfactory bulb out. Of
course, mixture. Then we culture them and purify
them . . . 90 percent olfactory ensheathing cells
(OECs).” The observational data obtained in
regard to the transplant material are more com-
plex. Guest and others recently published the
results of immunostaining 2 cell cultures provided
by Dr Huang.16 The cells appeared viable and were
positive for the markers nestin and GFAP but nega-
tive for S-100. These cells were not clearly OECs
but appeared to be astrocytes and immature cells.
Dr Guest was not permitted to visit the cell culture
facility in Beijing to verify the cell preparation pro-
cedures. Details of the cell preparation have never
been released.
Concerns about the type of cell implanted have
also been raised at meetings in which Dr Huang
has presented his videotapes. Identification of
small structures such as olfactory bulbs in fetal tis-
sue specimens obtained from early therapeutic
10 Neurorehabilitation and Neural Repair 20(1); 2006
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abortions is considered difficult, and the earliest
developmental age at which the human olfactory
bulb becomes populated by OECs is uncertain.
The outer glomerular layer that Huang and others7
have reported as their source of cells has not been
shown to be a source of fetal OECs and contains
many cell types, most commonly astrocytes. Fur-
thermore, the fetal olfactory bulb almost certainly
contains cells with progenitor capacity. Thus, in
the absence of compelling evidence, the cells
transplanted in Beijing should be identified as
human fetal cells, possibly of olfactory bulb origin.
The nature of the implanted cells is a critical
issue for future transplantation investigations. Dr
Huang has drawn on the limited success of inject-
ing adult-derived OECs into animal models of
SCI.17,18 No published reports of fetal OECs, how-
ever, have claimed to improve outcomes in experi-
mental animal models of SCI. The only report of
the use of purified fetal OECs in spinal cord contu-
sion indicated that the cells did not associate with
axons.19 Also, no animal studies have been re-
ported in which OECs were injected into the brain
to address the problem of SCI. Autologous adult
OECs have been injected into the spinal cord of
human subjects in a safety trial.20
Entry criteria and the clinical goal for the proce-
dure were unclear in the 7 cases and in observa-
tions by Dr Guest. Other patients have been
implanted for diseases such as transverse myelitis,
despite prior surgical interventions such as
omental transplants to the cord, as well as for
symptoms of pain, spasticity, or a self-selected
subjective goal.
SOLUTIONS
Understanding Anecdotal Success
A few alternative explanations may account for
the very modest changes occasionally observed or
perceived by recipients. Immediate postoperative
hypotonicity was apparent in 4 of the subjects in
this report, all of whom had a history of symptom-
atic spasticity. A decrease in clonus and spasms
was also evident in some of Dr Huang’s videos and
was mentioned in several media reports. Manipu-
lation of the spinal cord by laminectomy, incision
of the dura mater, and injections of cells, as well as
induction of an immunologic response or aseptic
meningitis or both, could have altered periop-
erative spasticity. Hypertonicity returned within 10
days after surgery in all subjects. Any changes in
movement are not expected to outlast the return of
hypertonicity. Of interest, Reier21 also reported
less spasticity and excitability shortly after spinal
implant surgery or after filling a syrinx with
embryonic tissue.
After leaving China, some patients may have
achieved gains from participating in rehabilitation
therapies. All 7 subjects studied before and after
surgery had not had recent preoperative physical
therapy but worked daily with therapists and their
families after returning from Beijing. Progressive
practice is a cornerstone of rehabilitation and physi-
ologic neuroplasticity. Modest gains commonly
evolve, regardless of the duration of a brain injury or
SCI, in patients who retain some level of motor
control.22,23
Psychologic and cultural factors always play an
important role in the perception of the benefits of a
new approach for patients with chronic neurologic
diseases. Randomized trials with a control inter-
vention explicitly try to limit this effect. Patients
often express frustration by their perception that
experimental therapies available outside of their
country are prohibited in their country because of
overly cautious regulatory agencies or the use of
aborted fetal tissue and stem cells.6 A strong per-
sonal belief in the expected benefits of the inter-
vention and the influence of a physician and an
environment that expects improvement may bias
postoperative personal perceptions. That interna-
tional patients pay at least $20 000 for the implant
procedure6 may both confirm and bias their assess-
ment of the strategy. One of the families among the
7 case studies raised $50 000 for the procedure,
their own nurse, and travel expenses. This finan-
cial stake in the outcome may also bias patient sat-
isfaction, in that any potential opportunity to get
better is worth purchasing, regardless of the final
result.
Reaching Out to
Patients and Practitioners
The procedures in Beijing do not meet the basic
qualifications of a controlled experiment by cur-
rently accepted international standards. As per-
formed, no scientific or clinical questions about
transplantation for chronic SCI have been
addressed. The academic community, patient
advocacy groups, and the media must help
encourage the utilization of internationally devel-
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oped standards when new biologic interventions
are introduced.
Academic Medicine
The neuroscience, medical, biomedical, and
rehabilitation community must take on greater
responsibility for airing problematic applications
for the translation of basic research. Caution and
courtesy are important, considering the dedication
and resources invested in controversial interven-
tions, but should not interfere with frank discus-
sion and critical analysis when major methodologi-
cal issues become manifest. The academic
community should continue to emphasize that
complex human experiments in neural repair for
severely disabled patients must be proven safe and
effective by the highest standards of scientific
inquiry.20 Alternative methodological and ethical
opinions should be openly discussed to assess
their validity and utility. Dr Huang was reported as
saying that a placebo or sham surgery would be
unethical.24 “Even if it was [legal],” he said, “I
wouldn’t do it. Double-blind trials only harm the
patient.” In contrast to Dr Huang’s opinion, pla-
cebo-controlled randomized trials conducted in
China have been reported in prestigious Western
journals.25 Indeed, current guidelines for clinical
trials, such as the International Conference on Har-
monisation Tripartite Guidelines,26,27 or specifi-
cally for SCI9,28 should be incorporated into every
experiment with human subjects. The worldwide
research and clinical community must help dis-
abled persons and their advocates understand the
fundamental value of guidelines and peer review
and how these safeguards protect the welfare of
patients.
Advocacy Groups
Groups that represent the neuroscience com-
munity of clinical and basic researchers, as well as
nonprofit groups that fund and educate patients
with SCI and other neurologic diseases, must con-
tinue to find ways to better inform and counsel
patients and families who seek controversial thera-
pies. Advocacy groups can make it clear that par-
ticipation in invasive surgical interventions for SCI
may disallow their participation in any future clini-
cal trial of a biologic therapy. Clinicians and
nonprofits should offer a logical counterpoint to
the nonskeptical enthusiasm often found on Web
sites and Internet chat rooms by explaining why
the methods, such as those being used in Beijing,
fail scientifically and ethically. It may be counter-
productive, however, to condemn an intervention
or aggressively discourage patients without invit-
ing discourse. The immediate allure of a new inter-
vention such as cellular transplantation for a dis-
abling condition requires objective, arms-length
counseling about the specific details of the risks
and likely benefits of a procedure. If the procedure
is not conducted by a methodology that meets vali-
dated international standards to determine its
safety and efficacy, participation should be
strongly discouraged.
Media
Newspaper, Web-based, and television reports
about new research findings and interventions for
diseases can have a profound effect on patients
who are seeking a cure. Testimonials played by
Western media have had an important role in
bringing Dr Huang’s experiment to patients with
SCI.11 The media must strive to look critically at
uncorroborated or overreaching reports. For
example, media outlets and prestigious scientific
journals including Science and Nature have
repeatedly stated that Dr Huang is transplanting
OECs, despite the lack of objective data to validate
this claim.24 An emphasis on subtle and transient
sensorimotor changes such as a toe that wiggles,
rather than functionally beneficial gains, fill these
stories.24,29,30 Too often, inspiring phrases such as
“China leads the world in the fetal stem cell trans-
plant field” and “pioneering medical procedures”
bias stories about patients who have traveled to
China for treatment.24 For example, a CBS News
report on July 27, 2004, on the use of implants in
Beijing for ALS and SCI included the troublesome
and unsubstantiated remark, “American neurologi-
cal experts say this is good science.”29 In covering
the translation of scientific research into medicine,
reporters could address concerns as to whether
international standards for the protection of
human subjects, which includes the proper use of
patients to determine the safety and efficacy of a
new drug or biological procedure, are being met.
CONCLUSION
Based on the observations in this series of 7 sub-
jects, the safety and efficacy of Dr Huang’s implan-
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tation procedure are unclear. Patients have
encountered serious medical complications and
no lasting increase in sensorimotor function or
functional ability.
Controversial medical interventions may seem
to be a reasonable risk for people living with seri-
ous disability from SCI and a way to overcome the
limited expectations they perceive within their
medical systems. Some patients find value in the
atmosphere of hope that is inherent in new
approaches offered by a confident practitioner.
Positive nurturing, however, is not outweighed by
potential risk without benefit from an unsubstanti-
ated clinical practice. The Beijing program’s meth-
odology has prevented the determination of safety
and efficacy for this cell-based approach. Until
international standards for scientific trial method-
ologies have been incorporated, clinicians are
obligated to advise their patients to forgo Dr
Huang’s procedure.
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